Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Longitudinal associations of cardiovascular health and vascular events with incident dementia.

Stroke and vascular neurology·2023
Same author

Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy.

Journal of Parkinson's disease·2023
Same author

Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.

Molecular neurobiology·2023
Same author

Association of biological age with health outcomes and its modifiable factors.

Aging cell·2023
Same author

The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study.

Journal of neurochemistry·2023
Same author

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.

Molecular neurodegeneration·2023
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Mei Cui1,2, Yu-Yuan Huang3, Yiren Fan2

  • 1MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

这项III期试验表明,18F-florzolotau (18F-APN-1607) PET成像是一种敏感和特定的工具,用于诊断阿尔茨海默病 (AD) 和因AD而轻度认知障碍 (MCI). 标记物是安全的,与疾病严重程度相关.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 放射化学 放射化学是指辐射化学.
  • 医疗成像医学成像

背景情况:

  • 阿尔茨海默病 (AD) 的特点是β-粉样蛋白 (Aβ) 和tau病理.
  • 18F-florzolotau (18F-APN-1607) 能够在AD和非AD条件下进行高对比度tau成像.
  • 之前的试验评估了18F-APN-1607的药理动力学,安全性和诊断疗效.

研究的目的:

  • 为了证明18F-APN-1607的敏感性,特异性和安全性,用于诊断AD和AD痴呆症导致的MCI.
  • 要突出TAU病理阶段和AD患者的临床严重程度之间的相关性.

主要方法:

  • 一个多中心的III期临床试验,涉及30名健康志愿者,100名因AD而患有MCI和100名AD痴呆症患者.
  • 使用主观阅读分析和基于SUVR的阅读分析来确定tau沉积的灵敏度和特异性.
  • 评估了安全性和耐受性,并探索了18F-APN-1607 SUVR,Braak分期和临床严重程度之间的相关性.

主要成果:

  • 对18F-APN-1607 PET的高诊断准确度,使AD与健康志愿者区分开来 (MTL中的AUC为0.982,新皮质中的AUC为0.979).
  • 在区分MCI与健康志愿者的准确性很好 (MTL中的AUC为0.842,新皮质中的AUC为0.869).
  • 没有报告严重不良事件;观察到与布拉克阶段和临床严重程度相关的明显的积模式 (CDR,MMSE,ADAS-cog得分).

结论:

  • 18F-APN-1607在诊断AD时表现出良好的特异性和敏感性.
  • 标记器是安全和可靠的AD诊断.
  • 18F-APN-1607可以作为跟踪AD进展和认知衰退的生物标志物.